| Summary: | Arterial hypertension is an independent predictor of acute myocardial infarction. Nowadays, plasma levels of fibronectin and matrix metalloproteinase 9 are the markers of left ventricular remodeling.
The objective of the research was to investigate potential antifibrotic effects of Quercetin in patients with acute myocardial infarction and arterial hypertension.
Material and methods. 130 patients with myocardial infarction (63 individuals with concomitant arterial hypertension and 67 individuals without it) were observed. All the patients were divided into groups of basic treatment and additional prescription of Quercetin. Transthoracic echocardiogram was used. To evaluate plasma level of fibronectin and matrix metalloproteinase 9 the ELISA method was applied.
Results. In all the patients, a significant decrease in fibronectin plasma levels was observed since the 28th day of treatment; however, it was more significant in group of additional prescription of Quercetin. Revascularization and pharmacological management of myocardial infarction resulted in the reduction in matrix metalloproteinase 9 plasma levels in all the patients since the 7th day of treatment; however, it was more significant in group of additional prescription of Quercetin.
Conclusions. Quercetin possesses potential antifibrotic properties causing a reduction in plasma levels of fibronectin and matrix metalloproteinase 9 in patients with myocardial infarction and concomitant arterial hypertension.
|
|---|
